Table 1.
Trial characteristics.
| Trial | Median Follow up (months) | Number of patients | Treatment before randomization | Post- surgery adjuvant RT to breast (%) | HR positive | HER2 positive | Triple Negative | Pre-menopausal | Visceral disease | Bone only disease | Surgery in control arm |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Badwe 2017 [10] | 23 | 350 | Systemic Therapy | 80% | 60% | 31% | NA | 46% | 71% | 29% | 11% |
| Soran 2018 [11] | 40 | 274 | Upfront surgery | 58% | 78% | 31% | 12% | 58% | 54% | 46% | 6% |
| Fitzal 2019 [9] | 37.5 | 90 | Upfront surgery | 20% | 81% | 22% | 9% | 13% | 62% | 38% | 15% |
| Khan 2020 [12] | 53 | 256 | Systemic Therapy | 60% | 58% | 32% | 8% | 36% | 65% | 38% | 19% |
Abbreviations: HER2 – human epidermal growth factor receptor 2, HR – hormone receptor, RT-radiotherapy.